Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
InflaRx NV (IFRX)
NASDAQ:IFRX
Holding IFRX?
Track your performance easily
IFRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.17 - $2.82
Previous Close$2.24
Volume88.74K
Average Volume (3M)244.03K
Market Cap
$125.42M
Enterprise Value$113.19M
Total Cash (Recent Filing)€12.77M
Total Debt (Recent Filing)€1.12M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Mar 20, 2025EPS Estimate
-$0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding58,883,272
10 Day Avg. Volume663,002
30 Day Avg. Volume244,032
Standard Deviation0.32
R-Squared0.07
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)1.29
Price to Sales (P/S)1784.10
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.00Price Target Upside301.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
InflaRx News
PremiumCompany Announcements
InflaRx Begins Phase 2a Trial for Innovative Anti-Inflammatory Drug
PremiumCompany Announcements
InflaRx Gets EMA Nod for COVID-19 Treatment
PremiumCompany Announcements
InflaRx Reports Q3 2024 Financial Results and Progress
PremiumCompany Announcements
InflaRx Reports Rising Revenue Amidst Significant LossesBulls Say, Bears Say
Bulls Say
Clinical Trial SuccessGohibic treatment showed a significant reduction in 28-day all-cause mortality by 23.9% in critically ill COVID-19 patients, highlighting its potential to improve survival rates.
Financial StabilityInflaRx has sufficient cash and marketable securities to fund operations into 2026, ensuring financial stability for ongoing and future developments.
Regulatory ApprovalThe European Commission is expected to adopt a positive opinion and issue a marketing authorization for Gohibic, which targets acute respiratory distress syndrome caused by SARS-CoV-2.
Bears Say
Financial StrategyInflarx does not expect its commercialization approach for Gohibic in Europe to have a meaningfully negative impact on its cash burn rate, implying limited resource allocation for the launch.
Regulatory ChallengesThe FDA indicated that InflaRx would need to conduct an additional well-controlled and adequately powered study in a broader ARDS setting for it to obtain a biologics license application.
Sales PerformanceSales of Gohibic have materialized slower than expected.
---
Ownership Overview
―
Insiders
0.06% Mutual Funds
18.81% Other Institutional Investors
81.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IFRX FAQ
What was InflaRx NV’s price range in the past 12 months?
InflaRx NV lowest stock price was $1.17 and its highest was $2.81 in the past 12 months.
What is InflaRx NV’s market cap?
Currently, no data Available
When is InflaRx NV’s upcoming earnings report date?
InflaRx NV’s upcoming earnings report date is Mar 20, 2025 which is in 88 days.
How were InflaRx NV’s earnings last quarter?
InflaRx NV released its earnings results on Nov 08, 2024. The company reported -$0.311 earnings per share for the quarter, missing the consensus estimate of -$0.259 by -$0.052.
Is InflaRx NV overvalued?
According to Wall Street analysts InflaRx NV’s price is currently Undervalued.
Does InflaRx NV pay dividends?
InflaRx NV does not currently pay dividends.
What is InflaRx NV’s EPS estimate?
InflaRx NV’s EPS estimate is -$0.25.
How many shares outstanding does InflaRx NV have?
InflaRx NV has 58,883,270 shares outstanding.
What happened to InflaRx NV’s price movement after its last earnings report?
InflaRx NV reported an EPS of -$0.311 in its last earnings report, missing expectations of -$0.259. Following the earnings report the stock price went up 3.311%.
Which hedge fund is a major shareholder of InflaRx NV?
Among the largest hedge funds holding InflaRx NV’s share is Woodline Partners LP. It holds InflaRx NV’s shares valued at N/A.
---
InflaRx Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (301.79% Upside)
$9.00 (301.79% Upside)
Hedge Fund Trend
Decreased
By 173.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.33%
12-Months-Change
Fundamentals
Return on Equity
-62.38%
Trailing 12-Months
Asset Growth
-35.13%
Trailing 12-Months
Company Description
InflaRx NV
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
---
IFRX Stock 12 Month Forecast
Average Price Target
$9.00
▲(301.79% Upside)
Technical Analysis
Best Analysts Covering IFRX
1 Year
1 Year Success Rate
10/20 ratings generated profit
1 Year Average Return
+19.54%
reiterated a buy rating last month
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +19.54% per trade.
---